Asthma Spacers Market - Forecasts from 2024 to 2029

The asthma spacers market is expected to reach a value of US$2,698.043 million by 2029, growing at a CAGR of 4.84% It was valued at US$1,937.567 million in 2022.

An asthma spacer is a holding chamber attached to an asthma medicine dispensing machine, commonly known as an inhaler, facilitating slower and more effective inhalation of the medicine. An asthma inhaler converts the medicine into gas form and delivers it to the patient’s lungs, opening the airways. However, the inhaler has less mouth space and rushes the medicine into the person's airways, making it hard to inhale the medicine and even leading to wastage.

A spacer is attached to the inhaler, a long tube that enables patients to slowly inhale the medicine, reducing wastage and enabling better inhalation. Increasing cases of asthma owing to the rise in pollution and growing cases of chronic diseases are expected to drive the market growth during the forecasted period. Rising cases of asthma, especially among children, are expected to drive the market demand since children find it difficult to inhale through the inhaler directly.

Market Drivers:

Growing cases of asthma, especially among children, have raised concerns and increased market adoption of asthma inhalers and spacers.

Asthma, particularly among children, is gaining popularity due to factors such as the need for specialized care, early onset, awareness, and advancements in asthma management. Asthma inhalers and spacers are recommended to ensure proper medication delivery and treatment efficacy. The growing awareness of asthma symptoms and early diagnosis has led to more individuals seeking medical attention. Advancements in asthma management and patient education programs are contributing factors to this trend.

Asthma is a widely prevalent respiratory chronic disease that affects the airways, making it difficult for the person to breathe owing to narrowed and/ or swollen up airways. One of the prime reasons expected to drive the asthma spacers market growth is the increasing cases of asthma worldwide, especially among children. Data from the Asia Pacific Association of Allergy, Asthma, and Clinical Immunology (PACI) shows that globally, more than 3 billion people suffer from asthma.

The World Health Organization (WHO) database shows that 461,000 people died because of this disease in 2019. Increasing cases of asthma owing to family genetics and rising air pollution are expected to increase the adoption of asthma inhalers and spacers, driving the market growth during the forecast period.

Increasing clinical acceptance of inhaled therapies is driving up demand for asthma spacers.

The asthma spacers market is growing due to the enhanced medication delivery, improved technique, reduced side effects, ease of use for children and elderly patients, and reduced systemic absorption of inhaled medications. These devices help patients overcome challenges related to coordination and timing, leading to better clinical outcomes. They also help reduce the deposition of medication in the mouth and throat, minimizing potential side effects.

The user-friendly interface of spacers makes it easier for these populations to receive their prescribed medications, improving patient compliance. Spacers also help reduce systemic absorption, directing a higher proportion of the drug to the lungs. They also increase medication deposition in the lungs, enhancing asthma control. Patient education and training programs are also growing, and clinical evidence supporting spacer use is growing.

The integration of smart inhaler technologies with spacers further enhances their appeal. Asthma spacers align with global efforts for better asthma control, contributing to market growth.

Market Restraints

The development of spacer-free technology to reduce the overall cost of medication constraints the market growth of asthma spacers.

The WHO recommends using homemade replacements and spacer-free technology to lower the overall cost of medication, which is what is limiting the market growth of asthma spacers. The WHO aims to reduce global asthma under its Global Action Plan for the Prevention and Control of NCDs, 2030.

A study by the organization observed that only 1/5th of patients suffering from asthma have access to inhalers, and the majority were not aware of the usage and importance of spacers. In its guidelines and awareness programs, WHO promoted the making and usage of homemade spacers using plastic bottles, which could be substituted for branded asthma spacers. The low cost of homemade spacers, accompanied by high treatment and medication costs, encourages the adoption of DIY spacers, especially in low-income countries, and hence constraints the prospective opportunity for the market.

Growth of products that do not need to be inhaled with spacers could hinder the asthma spacers market.

The development of technology and the launch of new products that do not require a spacer for inhalation pose a significant market threat for asthma spacers. Teva Pharmaceuticals. for instance, has successfully formulated spacer-free asthma medication, which enables better breathing for the patients. QVAR® RediHaler™ is an FDA-approved spacer-free technology that delivers medication as effectively as its predecessor. QVAR® RediHaler™ has been developed around breath-actuated inhaler technology and is apt for four-year-old and older patients, which can be used without the spacer, even for children. The rise in such technology is expected to hinder the market for the asthma spacer industry.

Key Developments:

• November 2023-Monaghan Medical Corporation was awarded the 2023 Zenith Award by the American Association for Respiratory Care (AARC). The award is prestigious for its exceptional products, accessible sales staff, responsiveness, service record, truth in advertising, and unwavering support of the respiratory care profession. The award was presented at the AARC's 67th International Respiratory Convention & Exhibition in Nashville, Tennessee, highlighting Monaghan Medical's commitment to excellence in respiratory care.
• March 2023-GSK plc accepted a new drug application for Nucala (mepolizumab) as an add-on maintenance treatment for severe eosinophilic asthma (SEA). If approved, Nucala would be the first targeted anti-interleukin-5 (IL-5) treatment in China for adult and adolescent patients with SEA. The application is based on positive data from a phase III trial among Chinese patients and the global SEA development program. Asthma affects an estimated 46 million adults in China, with 6% experiencing severe asthma. Nucala is currently approved in China for adults with eosinophilic granulomatosis with polyangiitis.

Key Market Segments

By Product Type

• AeroChamber
• OpticChamber
• Easivent
• Others

By Distribution Channel

• Online
• Offline

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• Spain
• France
• Others
• Middle East and Africa
• UAE
• Saudi Arabia
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Taiwan
• Thailand
• Indonesia
• Others